Inpharma Weekly

, Volume 1215, Issue 1, pp 6–7 | Cite as


a vital role in breast cancer disease management
  • Amanda Cameron
Newsletter Article


When choosing which disease management programmes to fund, health maintenance organisations must consider both the needs of its membership and the realities of economic survival - what is good for patients is not necessarily good for the bottom-line. In the case of breast cancer, a programme encouraging the use of the hormonal drug tamoxifen would provide clear benefits for women since the agent has been shown to reduce the risk of breast cancer by 49%. But what about the cost of such a programme? Researchers at the 4th Annual Disease Management Congress [ Boston, Massachusetts, US; October 1999 ] presented data examining the cost of breast cancer in two managed-care populations and the impact of a breast cancer risk management programme.


Breast Cancer Tamoxifen Breast Cancer Risk Disease Management Programme Health Maintenance Organisation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Copyright information

© Adis International Ltd 1999

Authors and Affiliations

  • Amanda Cameron

There are no affiliations available

Personalised recommendations